The effects of cytotoxic therapy in progressive IgA nephropathy
| العنوان: | The effects of cytotoxic therapy in progressive IgA nephropathy |
|---|---|
| المؤلفون: | Jung Eun Lee, Yoon-Goo Kim, Dae Joong Kim, Hye Ryoun Jang, Sin-Ho Jung, Ghee Young Kwon, Ji Hyeon Park, Ha Young Oh, Sharon Lim, Wooseong Huh, Jung-ho Shin |
| المصدر: | Annals of Medicine. 48:171-181 |
| بيانات النشر: | Informa UK Limited, 2016. |
| سنة النشر: | 2016 |
| مصطلحات موضوعية: | Adult, Male, medicine.medical_specialty, Biopsy, Urinary system, 030232 urology & nephrology, Urology, Renal function, Angiotensin-Converting Enzyme Inhibitors, 030204 cardiovascular system & hematology, Kidney, Kidney Function Tests, urologic and male genital diseases, Lower risk, Nephropathy, End stage renal disease, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Internal medicine, Republic of Korea, medicine, Humans, Cyclophosphamide, Retrospective Studies, Creatinine, Proteinuria, Cytotoxins, business.industry, Glomerulonephritis, IGA, General Medicine, Middle Aged, medicine.disease, Treatment Outcome, Endocrinology, medicine.anatomical_structure, chemistry, Disease Progression, Kidney Failure, Chronic, Female, medicine.symptom, business, Angiotensin II Type 1 Receptor Blockers, Immunosuppressive Agents, Follow-Up Studies, Glomerular Filtration Rate |
| الوصف: | IgA nephropathy (IgAN) is not always benign, and some patients at high risk of end-stage renal disease (ESRD) experience a rapid decline in renal function. This study retrospectively examined the beneficial effects of cytotoxic therapy.We identified 102 patients with progressive IgAN despite optimal conservative management. Of these, 31 who received cytotoxic therapy and 55 who were managed conservatively were included.Median eGFR and urinary protein-to-creatinine ratio (uPCR) at baseline did not differ between the groups (p = 0.475 and 0.259, respectively). Median GFR slope was also similar (p = 0.896). Cumulative renal survival was better in the cytotoxic therapy group than in the control group (p = 0.009). Cytotoxic therapy was associated with lower risk of progression to ESRD, independent of eGFR, uPCR, GFR slope and kidney histologic findings (HR 0.13, 95% CI 0.03-0.66). In the cytotoxic therapy group, the median GFR slope decreased from -7.8 (-10.5, -5.0) mL/min/1.73 m(2) per year to -3.4 (-5.1, -1.8) mL/min/1.73 m(2) per year after treatment (p 0.001). Mortality was not observed, but infection requiring hospitalization occurred at similar rates in both groups (p = 0.886).Cytotoxic therapy attenuated the rate of GFR decline and was associated with a favorable renal outcome in patients with progressive IgAN. |
| تدمد: | 1365-2060 0785-3890 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca8f0869279bee35134f58bddd3b2626Test https://doi.org/10.3109/07853890.2016.1153805Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....ca8f0869279bee35134f58bddd3b2626 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 13652060 07853890 |
|---|